"Descrizione" by AColumn (9309 pt) | 2019-Nov-17 10:57 |
Evaluation | N. Experts | Evaluation | N. Experts |
---|---|---|---|
1 | 6 | ||
2 | 7 | ||
3 | 8 | ||
4 | 9 | ||
5 | 10 |
Bisoprolol, a derivative of phenoxy-2-propanol, is a drug widely used to treat chronic heart failure as a free base or conjugate base of bisoprolole-fumarate in transdermal, tablet form.
It is a beta-blocker also used in the treatment of hypertension, atrial fibrillation, postural tachycardia syndrome, angina and arrhythmia.
Antihypertensive drugs in the form of transdermal patches in particular are considered clinically significant as they allow stable control of diastolic pressure (1).
It exerts an antioxidant activity and, due to its lipophilic nature, facilitates the passage in the brain tissue to produce therapeutic actions on central neurons (2).
In a comparison, the tolerability, effectiveness and safety of bisoprolol and carvedilol do not show significant differences (3).
Like all drugs it can cause side effects. Always consult your doctor.
Molecular Formula: C18H31NO4
Molecular Weight: 325.4 g/mol
CAS: 66722-44-9
EC Number: 615-996-8
DSSTox Substance ID: DTXSID6022682
MDL number MFCD00865795
PubChem Substance ID 329757631
Synonyms:
References_________________________________________________
(1) EFFECT OF HYDROPHILIC AND HYDROPHOBIC POLYMER ON IN VITRO DISSOLUTION AND PERMEATION OF BISOPROLOL FUMARATE THROUGH TRANSDERMAL PATCH. Shabbir M, Ali S, Raza M, Sharif A, Akhtar FM, Manan A, Fazli AR, Younas N, Manzoor I. Acta Pol Pharm. 2017 Jan;74(1):187-197.
(2) Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples. Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F. Pharmacology. 2018;101(1-2):29-34. doi: 10.1159/000480091.
(3) Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial. Tsutsui H, Momomura SI, Masuyama T, Saito Y, Komuro I, Murohara T, Kinugawa S; CIBIS-J Investigators. Circ J. 2019 May 24;83(6):1269-1277. doi: 10.1253/circj.CJ-18-1199.
Evaluate |